Krystal Biotech KB407 Selected For FDA Complex Innovative Trial Design Program
Share
Why It Matters
Krystal Biotech's medicine got picked for a special FDA program. This means the FDA thinks the drug is promising and wants to help test it faster.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.